Covered recipient · General Payments record
DILSHER S DHOOT
Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$408,770.50
345 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $205,575.07 | 30 |
| Consulting Fee | $145,888.00 | 73 |
| Travel and Lodging | $30,747.39 | 110 |
| Honoraria | $18,040.00 | 3 |
| Food and Beverage | $8,361.59 | 127 |
| Gift | $150.00 | 1 |
| Education | $8.45 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $118,423.08 | 115 |
| Ocular Therapeutix, Inc. | $98,273.91 | 57 |
| Apellis Pharmaceuticals, Inc. | $97,282.41 | 57 |
| Genentech USA, Inc. | $30,204.93 | 33 |
| Sandoz Inc. | $20,833.75 | 15 |
| Alimera Sciences, Inc. | $19,044.57 | 15 |
| Regeneron Pharmaceuticals, Inc. | $5,789.82 | 7 |
| EyePoint Pharmaceuticals US, Inc. | $4,833.01 | 5 |
| Bausch & Lomb Americas Inc. | $4,284.24 | 5 |
| BioCryst Pharmaceuticals, Inc. | $2,724.09 | 4 |
| Roche Products Limited | $2,520.00 | 1 |
| ABBVIE INC. | $1,221.24 | 5 |
| Beaver-Visitec International, Inc. | $1,200.00 | 1 |
| NEW WORLD MEDICAL,INC. | $534.96 | 4 |
| Genentech, Inc. | $461.38 | 2 |
| Astellas Pharma US Inc | $344.04 | 9 |
| Harrow Eye, LLC | $301.24 | 3 |
| Avirmax Biopharma, Inc | $150.00 | 1 |
| Topcon Healthcare, Inc. | $145.70 | 1 |
| Janssen Pharmaceuticals, Inc | $84.77 | 2 |
| Coherus Biosciences Inc. | $67.63 | 1 |
| Biogen, Inc. | $45.73 | 2 |
Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DILSHER S DHOOT
NPI 1508070566 · CMS profile ID 1089026
Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist
SANTA BARBARA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DILSHER S DHOOT, NPI 1508070566, CMS profile ID 1089026. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). DILSHER S DHOOT, NPI 1508070566, CMS profile ID 1089026. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- DILSHER S DHOOT, NPI 1508070566, CMS profile ID 1089026, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
345 matching records · $408,770.50 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 345.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $54.00 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037341 | CMS |
| Regeneron Healthcare Solutions, Inc. | $19.90 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037343 | CMS |
| Regeneron Healthcare Solutions, Inc. | $12.85 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037345 | CMS |
| Regeneron Healthcare Solutions, Inc. | $29.75 | 05/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037347 | CMS |
| Astellas Pharma US Inc | $160.00 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139341142 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 05/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148198221 | CMS |
| NEW WORLD MEDICAL,INC. | $186.92 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137397731 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5,290.00 | 05/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037317 | CMS |
| Regeneron Healthcare Solutions, Inc. | $7,935.00 | 05/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037319 | CMS |
| Astellas Pharma US Inc | $27.76 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139333110 | CMS |
| BioCryst Pharmaceuticals, Inc. | $24.09 | 05/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117472690 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 05/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148198217 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 05/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148198267 | CMS |
| Regeneron Pharmaceuticals, Inc. | $33.48 | 05/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114398249 | CMS |
| Ocular Therapeutix, Inc. | $1,500.00 | 05/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148198247 | CMS |
| Regeneron Healthcare Solutions, Inc. | $124.73 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037313 | CMS |
| Regeneron Healthcare Solutions, Inc. | $239.15 | 05/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037315 | CMS |
| Sandoz Inc. | $73.00 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089367256 | CMS |
| Regeneron Healthcare Solutions, Inc. | $30.66 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037309 | CMS |
| Regeneron Healthcare Solutions, Inc. | $152.30 | 05/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037311 | CMS |
| Genentech USA, Inc. | $397.88 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133002038 | CMS |
| Genentech USA, Inc. | $6,720.00 | 05/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133002042 | CMS |
| Genentech USA, Inc. | $209.84 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133002046 | CMS |
| Genentech USA, Inc. | $81.51 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133002050 | CMS |
| Genentech USA, Inc. | $743.60 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133002054 | CMS |
| Genentech USA, Inc. | $146.09 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133002058 | CMS |
| Regeneron Healthcare Solutions, Inc. | $99.29 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037307 | CMS |
| Regeneron Healthcare Solutions, Inc. | $340.75 | 04/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037297 | CMS |
| Regeneron Healthcare Solutions, Inc. | $395.60 | 04/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037299 | CMS |
| Regeneron Healthcare Solutions, Inc. | $369.29 | 04/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037301 | CMS |
| Regeneron Healthcare Solutions, Inc. | $398.98 | 04/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037303 | CMS |
| Regeneron Healthcare Solutions, Inc. | $308.12 | 04/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037305 | CMS |
| Regeneron Healthcare Solutions, Inc. | $10,580.00 | 04/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037295 | CMS |
| Ocular Therapeutix, Inc. | $1,500.00 | 04/24/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148198227 | CMS |
| Regeneron Healthcare Solutions, Inc. | $238.52 | 04/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037293 | CMS |
| Genentech USA, Inc. | $33.15 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133002034 | CMS |
| Regeneron Healthcare Solutions, Inc. | $54.10 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037291 | CMS |
| Regeneron Healthcare Solutions, Inc. | $577.50 | 04/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037287 | CMS |
| Regeneron Healthcare Solutions, Inc. | $253.50 | 04/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037289 | CMS |
| Regeneron Healthcare Solutions, Inc. | $239.28 | 04/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037283 | CMS |
| Regeneron Healthcare Solutions, Inc. | $0.01 | 04/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037285 | CMS |
| Regeneron Healthcare Solutions, Inc. | $40.00 | 04/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037273 | CMS |
| Regeneron Healthcare Solutions, Inc. | $9.95 | 04/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037275 | CMS |
| Regeneron Healthcare Solutions, Inc. | $12.31 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037277 | CMS |
| Regeneron Healthcare Solutions, Inc. | $15.38 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037279 | CMS |
| Regeneron Healthcare Solutions, Inc. | $29.75 | 04/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037281 | CMS |
| Regeneron Healthcare Solutions, Inc. | $59.95 | 04/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037271 | CMS |
| EyePoint Pharmaceuticals US, Inc. | $3,700.00 | 04/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089507278 | CMS |
| Regeneron Healthcare Solutions, Inc. | $35.62 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037269 | CMS |
| Apellis Pharmaceuticals, Inc. | $30.70 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154020036 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $24,711.52 | 7 |
| PY2025 | Principal investigator | $1,978,226.05 | 546 |
| PY2024 | Recipient | $67,234.88 | 20 |
| PY2024 | Principal investigator | $1,146,034.35 | 196 |
| PY2023 | Recipient | $10,830.67 | 7 |
| PY2023 | Principal investigator | $588,583.13 | 38 |
| PY2022 | Recipient | $7,047.37 | 4 |
| PY2022 | Principal investigator | $353,849.05 | 30 |
| PY2021 | Recipient | $9,275.99 | 5 |
| PY2021 | Principal investigator | $692,497.36 | 32 |
| PY2020 | Recipient | $29,746.12 | 15 |
| PY2020 | Principal investigator | $891,321.57 | 23 |
| PY2019 | Recipient | $7,478.66 | 8 |
| PY2019 | Principal investigator | $632,947.67 | 12 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
553 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,865.00 | 12/31/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231520 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $27,693.00 | 12/24/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231491 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,469.22 | 12/24/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231495 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,650.00 | 12/24/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231500 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $19,845.00 | 12/17/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231479 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,700.00 | 12/15/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231549 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $167.86 | 12/12/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362872 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $686.00 | 12/12/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362874 |
| Principal investigator 1 | Genentech, Inc. | $7,627.00 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582761 |
| Principal investigator 1 | Genentech, Inc. | $2,800.00 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274004 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274006 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274008 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274010 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274012 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274014 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274016 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274018 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274026 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274028 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274030 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274032 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274034 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274042 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274044 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274046 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274050 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274056 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274058 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274060 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274062 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274064 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274066 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274068 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274070 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274072 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274074 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274078 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274080 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274082 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274084 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274088 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184274092 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,001.81 | 12/10/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231462 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,951.54 | 12/10/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,302.85 | 12/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184268363 |
| Principal investigator 1 | Genentech, Inc. | $1,713.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582770 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,580.00 | 12/01/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.70 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267703 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267707 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267709 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267717 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267719 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267725 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267729 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267735 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267739 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/01/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184267741 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,300.00 | 12/01/2025 | Non-covered Recipient Entity California Retina Consultants | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100435 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,623.00 | 12/01/2025 | Non-covered Recipient Entity California Retina Consultants | Age-related macular degeneration | No dispute reported | 06/30/2026 | 1226100445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265217 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265221 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265223 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265225 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265227 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265229 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265231 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265237 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265239 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265245 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265249 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265251 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265253 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265255 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265257 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265263 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.70 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265265 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265269 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265277 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265279 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265287 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265293 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,580.00 | 11/19/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231405 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $121,098.00 | 11/19/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231410 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,004.00 | 11/19/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231418 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,477.37 | 11/14/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231397 |
| Principal investigator 1 | Genentech, Inc. | $665.00 | 11/13/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582753 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,640.00 | 11/12/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231371 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,635.00 | 11/12/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231375 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 11/12/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231378 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,133.64 | 11/12/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231387 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362836 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362838 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362840 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362842 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362844 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362846 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $872.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362848 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362850 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362852 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362854 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362856 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362858 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362860 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362862 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362864 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362866 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362868 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 11/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362870 |
| Principal investigator 1 | Genentech, Inc. | $485.00 | 11/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582757 |
| Principal investigator 1 | ABBVIE INC. | $899.10 | 11/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202520039 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,930.50 | 10/30/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184255705 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,633.00 | 10/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231360 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $16,440.00 | 10/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231362 |
| Principal investigator 1 | Genentech, Inc. | $4,596.00 | 10/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582741 |
| Principal investigator 1 | Genentech, Inc. | $3,106.00 | 10/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582745 |
| Principal investigator 1 | Genentech, Inc. | $300.00 | 10/15/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582736 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,350.00 | 10/15/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231545 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $200.00 | 10/13/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231527 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,969.00 | 10/10/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231352 |
| Principal investigator 1 | Genentech, Inc. | $1,132.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582749 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249222 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249224 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249226 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249228 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249230 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249232 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249234 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249242 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249244 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.70 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249252 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249254 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249256 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249258 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249260 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249262 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249264 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/09/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249266 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 10/08/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231326 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $845.00 | 10/08/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231333 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $192.50 | 10/02/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362834 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $29,259.00 | 10/01/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231322 |
| Principal investigator 1 | Genentech, Inc. | $18,197.00 | 09/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582729 |
| Principal investigator 1 | Genentech, Inc. | $13,552.00 | 09/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240984 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240988 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.70 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240990 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240992 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240994 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240996 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184240998 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241000 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241004 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241006 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241008 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241010 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241012 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241014 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241016 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241018 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241026 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241028 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241030 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241032 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241034 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241042 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241044 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241046 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241050 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241056 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241058 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241060 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241062 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241064 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241066 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241068 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241070 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241072 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241074 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241076 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241078 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241080 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241082 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241084 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56.70 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241088 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241092 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241096 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241108 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241110 |
| Principal investigator 1 | Genentech, Inc. | $485.00 | 09/18/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582722 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239742 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239744 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239746 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239748 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239750 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239752 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239754 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239756 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239762 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 09/17/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184239770 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $15,600.00 | 09/12/2025 | Non-covered Recipient Entity California Retina Consultants | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | No dispute reported | 06/30/2026 | 1250362732 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $5,000.00 | 09/12/2025 | Non-covered Recipient Entity California Retina Consultants | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | No dispute reported | 06/30/2026 | 1250362734 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,790.00 | 09/12/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231314 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,135.83 | 09/05/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184117041 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $20.00 | 09/03/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362742 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $120.00 | 09/03/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362744 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,769.00 | 09/03/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231282 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,483.80 | 09/03/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231286 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,974.51 | 09/03/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231289 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 09/03/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231293 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,790.00 | 09/03/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $18.55 | 09/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184234897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8.61 | 09/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184234899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184234903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184234905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184234907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $209.25 | 09/03/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184234909 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,836.00 | 08/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231268 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $34,579.00 | 08/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231272 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,862.00 | 08/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231275 |
| Principal investigator 1 | ABBVIE INC. | $1,603.80 | 08/27/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202506035 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $150.00 | 08/20/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362740 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $16,147.00 | 08/20/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231249 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23,069.00 | 08/20/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231253 |
| Principal investigator 1 | Genentech, Inc. | $300.00 | 08/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582725 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,790.00 | 08/13/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231223 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $13,740.00 | 08/13/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231241 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,026.00 | 08/06/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223850 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223852 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223962 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223964 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184223966 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224072 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224082 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $720.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222182 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,680.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222184 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $504.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $882.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222188 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $474.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222190 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,205.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222192 |
| Principal investigator 1 | ABBVIE INC. | $8,000.00 | 07/25/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202499772 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 07/25/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231203 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $872.00 | 07/23/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362736 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $872.00 | 07/23/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362738 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,013.19 | 07/18/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231166 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,548.92 | 07/18/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231175 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,790.00 | 07/18/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231191 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $4,830.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362746 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $872.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362748 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $872.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362750 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $872.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362752 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $872.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362754 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,053.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362756 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,561.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231153 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,055.32 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231158 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $42,448.00 | 07/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231162 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216116 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216118 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216120 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216122 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216124 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216126 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184216128 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6.09 | 07/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213696 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.11 | 07/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12.18 | 07/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184213700 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,889.00 | 07/09/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231146 |
| Principal investigator 1 | Genentech, Inc. | $10,762.00 | 07/07/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582718 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,972.20 | 07/04/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231133 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,601.00 | 07/04/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231137 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,790.00 | 07/02/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231115 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 07/02/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231124 |
| Recipient | Ocular Therapeutix, Inc. | $11,231.29 | 06/30/2025 | Covered Recipient Physician | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250229232 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $40.00 | 06/25/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362796 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $13.35 | 06/25/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362798 |
| Principal investigator 1 | Genentech, Inc. | $21,517.00 | 06/25/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582661 |
| Principal investigator 1 | Genentech, Inc. | $1,419.00 | 06/25/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582670 |
| Principal investigator 1 | Genentech, Inc. | $66,607.00 | 06/25/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582673 |
| Principal investigator 1 | Genentech, Inc. | $1,927.00 | 06/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582654 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 06/20/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362812 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 06/20/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362814 |
| Principal investigator 1 | Genentech, Inc. | $268.00 | 06/18/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582657 |
| Principal investigator 1 | Genentech, Inc. | $255.00 | 06/18/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582666 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $765.00 | 06/18/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231077 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $179.52 | 06/17/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184117039 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,082.20 | 06/13/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231065 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,106.00 | 06/13/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231069 |
| Principal investigator 1 | Genentech, Inc. | $485.00 | 06/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582650 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $686.00 | 06/11/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362800 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,790.00 | 06/11/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231061 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,641.40 | 06/06/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy | No dispute reported | 06/30/2026 | 1250231052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202025 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202027 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202029 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202031 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202033 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202035 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202427 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202717 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202719 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202721 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202723 |
| Principal investigator 1 | Genentech, Inc. | $485.00 | 05/28/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211582678 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $24,936.00 | 05/28/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231038 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,483.80 | 05/28/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3.36 | 05/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198687 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6.93 | 05/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198689 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $18.55 | 05/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198691 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $124.32 | 05/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198693 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6.09 | 05/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.11 | 05/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10.50 | 05/26/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198699 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,044.25 | 05/21/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231033 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $4,830.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362816 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $4,830.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362818 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362820 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362822 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362824 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362826 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362828 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362830 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,053.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362832 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $10,774.00 | 05/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231030 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $13,454.39 | 05/15/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | New Day Study | No dispute reported | 06/30/2026 | 1248567463 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $40.00 | 05/09/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362802 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $150.64 | 05/09/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362804 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,936.00 | 05/09/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231020 |
| Principal investigator 1 | Genentech, Inc. | $470.00 | 05/08/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582710 |
| Principal investigator 1 | Genentech, Inc. | $170.00 | 05/08/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582714 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $7,960.50 | 05/05/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184117037 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $44,639.00 | 04/30/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231006 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,052.00 | 04/30/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231009 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18,707.00 | 04/30/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231015 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $31,070.00 | 04/24/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | New Day Study | No dispute reported | 06/30/2026 | 1248567385 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184185573 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 04/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362806 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 04/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362808 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,053.00 | 04/16/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362810 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,016.24 | 04/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230972 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,953.05 | 04/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230984 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,377.00 | 04/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230988 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,790.00 | 04/16/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230994 |
| Principal investigator 1 | Genentech, Inc. | $32,667.00 | 04/11/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582704 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,500.00 | 04/09/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230953 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,000.00 | 04/09/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230957 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,863.00 | 04/09/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230961 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $250.00 | 04/09/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230965 |
| Principal investigator 1 | Genentech, Inc. | $5,253.00 | 04/08/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582696 |
| Recipient | F. Hoffmann-La Roche AG | $579.38 | 03/31/2025 | Covered Recipient Physician | VA2 PhIII Yosemite | No dispute reported | 06/30/2026 | 1211535444 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $25,515.00 | 03/21/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231095 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $4,830.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362766 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $4,830.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362768 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362770 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362772 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362774 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362776 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362778 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,053.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362780 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,053.00 | 03/14/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362782 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172776 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172778 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172780 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172782 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172784 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172786 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172788 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172790 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172792 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172794 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172796 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172798 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172800 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172802 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172804 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172806 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172952 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172954 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172956 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172958 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172960 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172964 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172966 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172968 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184172970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170682 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170684 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170686 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170688 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170692 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170694 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/10/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184170696 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23,131.00 | 03/07/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231088 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $437.00 | 03/05/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250231085 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156838 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156840 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184156846 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,872.00 | 02/26/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230929 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $2,350.00 | 02/19/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | New Day Study | No dispute reported | 06/30/2026 | 1248567457 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $4,830.00 | 02/19/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362758 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 02/19/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362760 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $23,958.00 | 02/19/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230909 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,580.00 | 02/19/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230913 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $686.00 | 02/07/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362764 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $8,811.00 | 02/05/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230883 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,500.00 | 02/05/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230898 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $11,200.00 | 01/30/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | New Day Study | No dispute reported | 06/30/2026 | 1248567541 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,921.00 | 01/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230936 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,810.00 | 01/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230940 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,211.00 | 01/29/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230945 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 01/28/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | No dispute reported | 06/30/2026 | 1211582681 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $3,710.75 | 01/24/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | New Day Study | No dispute reported | 06/30/2026 | 1248567433 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,140.00 | 01/24/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362784 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,668.00 | 01/24/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362786 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $55,468.00 | 01/22/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230901 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $750.00 | 01/20/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | New Day Study | No dispute reported | 06/30/2026 | 1248567691 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,273.00 | 01/17/2025 | Non-covered Recipient Entity California Retina Consultants | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250230891 |
| Principal investigator 1 | Genentech, Inc. | $335.00 | 01/16/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582689 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $2,055.00 | 01/14/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184117035 |
| Principal investigator 1 | Genentech, Inc. | $908.00 | 01/13/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | Port Delivery System of Ranibizumab Extension Study | No dispute reported | 06/30/2026 | 1211582685 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184147107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184147109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 01/08/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184147111 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $150.00 | 01/03/2025 | Non-covered Recipient Entity California Retina Consultants | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362762 |
| Recipient | Genentech, Inc. | $1,570.00 | 01/02/2025 | Covered Recipient Physician | Not supplied | No dispute reported | 06/30/2026 | 1211535448 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 01/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144570 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 01/02/2025 | Non-covered Recipient Entity CALIFORNIA RETINA CONSULTANTS | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184144572 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2019 | Amount invested | $0.00 | 1 |
| PY2019 | Value of interest | $3,360.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
1 record · PY2019
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2019 | US Retina LLC | $0.00 | $3,360.00 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 655842915 |